Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: Apoptotic tumor cell-derived microparticles loading Napabucasin inhibit CSCs and synergistic immune therapy

Fig. 2

NAP inhibited colon cancer by reducing STAT1 expression. A Western blot and RT-qPCR analysis of CD44 and BMI1 in NAP-treated CT26 cells. B Western Blot and RT-qPCR analyses of STAT1, STAT2, and STAT3 in the NAP-treated CT26 cells. C The correlations of STAT1, STAT2, and STAT3 with CD44 in human colon cancer tissues. D The heatmap of STAT1, STAT2, and STAT3 with CD44 in human colon cancer tissues. E Overexpression of STAT1 increased the protein levels of CD44. F Knockdown of STAT1 decreased the protein levels of CD44. G The overexpression of STAT1 reversed the effects of NAP on CD44 inhibition. H A STAT1 binding peak in the promoter region of CD44. I A consensus binding motif for STAT1. J The presence of STAT1 binding sites. K STAT1 bound to the promoter region of CD44

Back to article page

Journal of Nanobiotechnology

ISSN: 1477-3155

Contact us